Protective effects of azithromycin on adriamycin-induced nephropathy with albumin overload in mice

doi:10.12047/j.cjap.5879.2019.120

Abstract

Abstract: Objective: To study the protective effects of azithromycin on renal damage induced by doxorubicin and albumin in mice. Methods: Forty male BALB/c mice were randomly divided into blank control group (Ctrl group), renal damage model group (ADR+BSA group), azithromycin treated group (Azm group) and prednisone acetate positive control group (Pdn group) in accordance with random number table method. Mice in ADR+BSA, AZM and Pdn group were injected intravenously with 9.8 mg·kg^-1 doxorubicin five days a week, 10 mg·kg^-1 serum albumin was injected intraperitoneally, and normal saline was administered to the control group for 4 weeks to establish renal damage model. After that, AZM group was given daily. 62.5 mg·kg^-1 azithromycin was intragastrically administered. The Pdn group was given 12.5 mg·kg^-1 prednisone acetate daily, the other two groups were given the same amount of normal saline. After 6 weeks, the urine volume was collected and recorded for 24 hours to detected urine protein amount and endogenous creatinine clearance rate (Ccr). Serum biochemical indicators and serum immune factors were detected. Results: Compared with the Ctrl group, the 24 h urine protein level of the ADR+BSA group was increased significantly (P＜0.05), and the Ccr was decreased significantly (P＜0.05). After the azithromycin treatment, the 24 h urine protein was decreased significantly (P＜0.05), while the Ccr was increased significantly (P＜0.05) compared with ADR+BSA group. Conclusion: Azithromycin has a protective effects on the renal damage induced by doxorubicin and albumin in mice.

Key words: azithromycin, albumin overload, adriamycin, renal protection, mice

CLC Number:

R363

TANG Yi-hao, YIN Cheng-zhe, LI Kai, LI Wei-xin, FAN Chun-fang. Protective effects of azithromycin on adriamycin-induced nephropathy with albumin overload in mice[J]. CJAP, 2019, 35(6): 548-550.

References

[1] Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in iga nephropathy with proteinuria and renal dysfunction[J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313.
[2] Colucci M, Corpetti G, Emma F, et al. Immunology of idiopathic nephrotic syndrome[J]. Pediatric Nephrology, 2018, 33(4): 573-584.
[3] Külcü NU, Camcloglu Y, Aktas E, et al. The effect of systemic antibiotics, leukotriene receptor antagonist montelukast and azithromycin on Th1/Th2 cytokine levels in cystic fibrosis patients[J]. J Cyst Fibros, 2010, 9(S1): S49.53-60
[4] Cao Q, Wang Y, Zheng D, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis[J]. J Am Soc Nephrol, 2010, 21(6): 933-942.
[5] Yagmurca M, Erdogan H, Iraz M, et al. Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats[J]. Clin Chim Acta, 2004, 348(1-2): 27-34.
[6] 贺升升, 李爱平, 张王宁, 等. 阿霉素肾病模型及其病理机制研究进展[J]. 中草药, 2018, 49(22): 5426-5434.
[7] 李园园. IL-17及相关趋化因子在阿霉素肾病小鼠和足细胞中的作用机制研究 [D]. 山东大学, 2016.
[8] 支勇, 曹式丽.阿霉素肾病动物模型的国外研究进展[J]. 中国中西医结合肾病杂志, 2008, 9(10): 933-935.
[9] Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease[J]. Nat Rev Nephrol, 2015, 12(1): 37-47.
[10]Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis[J]. Nephrology, 2011, 16(1): 30-38.
[11]Okuda S, Oh Y, Tsuruda H, et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease[J]. Kidney Int, 1986, 29(2): 502-510.
[12]Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment[J]. Semin Nephrol, 2003, 23(2): 161-171.
[13]Tagawa A, Yasuda M, Kume S, et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy[J]. Diabetes, 2016, 65(3): 755-767.
[14]Kim JH, Xie J, Hwang KH, et al. Klotho may ameliorate proteinuria by targeting TRPC6 channels in podocytes[J]. J Am Soc Nephrol, 2017, 28(1): 140-151.
[15]杨维娜, 于琳华, 钱亦华, 等. 阿霉素肾病大鼠模型动态变化及其足细胞数量和nephrin的表达变化 [J]. 中山大学学报(医学科学版), 2009, 30(5): 512-516.
[16]Bobulescu IA. Renal lipid metabolism and lipotoxicity[J]. Curr Opin Nephrol Hy, 2010, 19(4): 393-402.
[17]李瑶, 魏心怡, 闫俊丽, 等. 白蛋白过载加重阿霉素肾病小鼠肾损害及辛伐他汀的肾脏保护作用[J]. 中国病理生理杂志, 2017, 33(2): 308-314.